Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307565 | 0.84 | P2RY1 (0.38) | P2RY1 | |
| SCHEMBL3157790 | 0.81 | CTSS (0.33) | ALDH1A1P2RY1 | |
| SCHEMBL3154428 | 0.80 | ALDH1A1 (0.42) | ALDH1A1P2RY1 | |
| SCHEMBL12681558 | 0.72 | GAA (0.33) | ALDH1A1 | |
| SCHEMBL3257799 | 0.71 | P2RY1 (0.45) | ALDH1A1P2RY1 | |
| SCHEMBL1135460 | 0.71 | P2RX3 (0.51) | ALDH1A1P2RY1 | |
| SCHEMBL3162794 | 0.69 | P2RY1 (0.65) | P2RY1 | |
| SCHEMBL7016888 | 0.69 | HPGD (0.42) | ALDH1A1ADORA2AADORA1 | |
| SCHEMBL1308056 | 0.69 | ALDH1A1 (0.37) | ALDH1A1P2RY1 | |
| SCHEMBL24654123 | 0.68 | P2RY1 (0.46) | P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | ALDH1A1 1978/4885ADORA2A 59/4885ADORA1 28/4885 |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | ALDH1A1 1978/4885ADORA2A 59/4885ADORA1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.